-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

Benzinga·09/10/2026 12:59:24
Listen to the news
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.